ReviewPharmaceutics2020
Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review.
Review in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 55 citations in OpenAlex.
- Corneal Extracellular Vesicles: Small Packages with a Big Impact.Pharmaceutics · 2026Review
- LNP-encapsulated miRNA29b for corneal repair: A novel approach to combat fibrosis.Materials today. Bio · 2025Article
- Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Review
- Biomedical Application of MSCs in Corneal Regeneration and Repair.International journal of molecular sciences · 2025Review
- Localization of fluorescent gold nanoparticles throughout the eye after topical administration.Frontiers in medicine · 2025Article
- The Emerging Role of Silk Fibroin for the Development of Novel Drug Delivery Systems.Biomimetics (Basel, Switzerland) · 2024Review
- Review
- Enhanced systematic delivery of fluconazole-loaded biotin-glutathione functionalized chitosan-g-proline carrier into the infected retinitis treatment.BMC ophthalmology · 2024Article
- Overview of processed excipients in ocular drug delivery: Opportunities so far and bottlenecks.Heliyon · 2024Review
- Emphasis on Nanostructured Lipid Carriers in the Ocular Delivery of Antibiotics.Pharmaceutical nanotechnology · 2024Review
- Assessing the Efficacy of PLGA-Loaded Antimicrobial Peptide OH-CATH30 Microspheres for the Treatment of Bacterial Keratitis: A Promising Approach.Biomolecules · 2023Article
- Functional Peptide-Loaded Gelatin Nanoparticles as Eyedrops for Cornea Neovascularization Treatment.International journal of nanomedicine · 2023Article
- Roles of biomaterials in modulating the innate immune response in ocular therapy.Frontiers in drug delivery · 2023Review
- Maleimide-Decorated PEGylated Mucoadhesive Liposomes for Ocular Drug Delivery.Langmuir : the ACS journal of surfaces and colloids · 2022Article
- Drug-Loaded Polymeric Particulated Systems for Ophthalmic Drugs Release.Molecules (Basel, Switzerland) · 2022Article
- Nanotechnology for Topical Drug Delivery to the Anterior Segment of the Eye.International journal of molecular sciences · 2021Review
- mRNA-Based Nanomedicinal Products to Address Corneal Inflammation by Interleukin-10 Supplementation.Pharmaceutics · 2021Article
- Deliver protein across bio-barriers via hexa-histidine metal assemblies for therapy: a case in corneal neovascularization model.Materials today. Bio · 2021Article
- Suppression of Intracellular Reactive Oxygen Species in Human Corneal Epithelial Cells via the Combination of Quercetin Nanoparticles and Epigallocatechin Gallate and In Situ Thermosensitive Gel Formulation for Ocular Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During recent decades, researchers all around the world have focused on the characteristic pros and cons of the different drug delivery systems for cornea tissue change for sense organs. The delivery of various drugs for cornea tissue is one of the most attractive and challenging activities for researchers in biomaterials, pharmacology, and ophthalmology. This method is so important for cornea wound healing because of the controllable release rate and enhancement in drug bioavailability. It should be noted that the delivery of various kinds of drugs into the different parts of the eye, especially the cornea, is so difficult because of the unique anatomy and various barriers in the eye. Nanoparticles are investigated to improve drug delivery systems for corneal disease. Biodegradable nanocarriers for repeated corneal drug delivery is one of the most attractive and challenging methods for corneal drug delivery because they have shown acceptable ability for this purpose. On the other hand, by using these kinds of nanoparticles, a drug could reside in various part of the cornea for longer. In this review, we summarized all approaches for corneal drug delivery with emphasis on the biodegradable nanoparticles, such as liposomes, dendrimers, polymeric nanoparticles, niosomes, microemulsions, nanosuspensions, and hydrogels. Moreover, we discuss the anatomy of the cornea at first and gene therapy at the end.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.